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Summary
To appreciate the significance of clinical trial 
results, clinicians need to understand the 
mathematical language used to describe 
treatment effects. When comparing intervention 
and control groups in a trial, results may be 
reported in terms of relative or absolute risk (or 
probability), or as more statistically sophisticated 
entities based on odds and hazard ratios. When 
events in the intervention group are significantly 
less frequent than in the control group, then 
relative risk, odds ratio and hazard ratio (and their 
confidence intervals) will be less than 1.0. If the 
converse holds true, these values will be greater 
than 1.0.
Key words: clinical trials, number needed to treat, odds, statistics.
(Aust Prescr 2008;31:12–16)
Introduction
In randomised trials and systematic reviews of trials, the effects 
of new treatments on dichotomous outcomes (such as death 
vs survival) can be expressed in several ways including relative 
risk, absolute risk, odds ratio and hazard ratio. These figures 
help to determine if the new treatment has an advantage over 
other treatments or placebo.
Ways of expressing treatment effects
The absolute risk, number needed to treat, relative risk and 
odds ratio can be calculated by compiling a 2x2 table of study 
data. Values can then be derived using the equations shown in 
the box.
Absolute risk
Absolute risk reduction, also termed risk difference, is the 
difference between the absolute risk of an event in the 
intervention group and the absolute risk in the control group. 
In a trial of 441 patients at risk of developing pressure ulcers, 
patients were randomised to receive a sheepskin mattress 
overlay (intervention group) or usual treatment (control group) 
during their hospital stay.1 The data from the trial can be 
represented in a 2x2 table (see Table 1).
Patients with 
ulcer(s)
Patients with 
no ulcers
Total 
patients
Sheepskin group 21 197 218
Control group 37 186 223
The absolute risk reduction can then be calculated by 
subtracting the proportion of patients with ulcers in the 
sheepskin group from that in the control group. 
37
223
21
218
= 0.07 (or 7.0%)
Almost 17% of patients in the control group developed ulcers 
compared to 10% in the sheepskin group after 20 days of 
observation. This means that the absolute risk of developing ulcers 
in the sheepskin group was 7% less than in the control group.
If a treatment is effective and reduces the risk of an unwanted 
event, we see an absolute risk reduction. Conversely, if the 
treatment does not work and in fact increases the risk of the 
event, then we see an absolute risk increase. 
It may be difficult to conceptualise the clinical relevance of the 
absolute risk reduction. The reciprocal of this value (1/absolute 
risk reduction) gives the number of patients who need to 
be treated for a certain period of time to prevent one event. 
Box
Calculations
Bad 
outcome
Good 
outcome
Total 
patients
Intervention group a c a+c
Control group b d b+d
measure equation
Absolute risk
Number needed  
to treat
Relative risk
Odds ratio
b
b+d
a
a+c
b
b+d
a
a+c
1
a
a+c
b
b+d
÷
a
a+c
c
a+c
÷
b
b+d
d
b+d
= a
c
÷ b
d
Table 1
Trial data
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This is termed the number needed to treat and can be useful 
for comparing the effectiveness of a number of different 
interventions. So in the ulcer trial, 14 patients need to have 
a sheepskin overlay for 20 days to prevent one of them from 
getting an ulcer. 
It is important to appreciate that absolute risk will vary 
according to the event rates in both patient groups, whereas the 
relative risk usually remains unchanged across the spectrum 
of disease severity (see Table 2). Putting this another way, in 
'low risk' patients (those with mild hypertension in Table 2) 
the absolute risk reduction will be small whereas in 'high risk' 
patients (those with moderate hypertension) absolute risk 
reduction will be larger. For both groups the relative risk (and 
relative risk reduction) is the same.2
Relative risk
Relative risk, also known as risk ratio, is the risk of an event in 
the experimental group divided by that in the control group.  
For the sheepskin trial, this can be calculated from the data in 
Table 1. 
In the trial, 10% of patients in the sheepskin group developed 
ulcers compared to 17% in the control group. So the risk of 
getting ulcers with a sheepskin overlay was 0.58 of that in the 
control group. 
In most trials where the treatment intends to prevent an 
undesirable outcome such as death or complication (prevention 
trials), efficacy will be denoted by a relative risk of less than 1.0. 
Treatment harm, reflecting an increased risk of an event (including 
adverse effect), will be denoted by a relative risk of more than 1.0. 
However, in trials where the treatment intends to reduce active 
disease (treatment trials) and promote a positive event, such as 
disease remission or symptom abatement, a relative risk of more 
than 1.0 confirms treatment efficacy. A relative risk of 1.0 indicates 
no difference between comparison groups. In all cases, statistical 
significance is assumed if the 95% confidence interval (CI) around 
the relative risk does not include 1.0. 
The relative risk reduction equals the amount by which the 
relative risk has been reduced by treatment and is calculated  
as 1 – relative risk. For example in the sheepskin trial, sheepskin 
overlays reduced the risk of patients getting ulcers by 0.42  
(1 – 0.58) or 42%. 
Odds ratio
Odds are the number of times an event happens divided by 
the number of times it does not within a group. Odds can also 
be expressed as the risk (or probability) of an event occurring 
over the risk of an event not occurring. To provide a numerical 
example: if 1/5 of the patients in a study suffer a stroke, the odds 
of their having a stroke is (1/5) ÷ (4/5) or 0.20/0.80, or 0.25. As the 
denominator is the same in both top and bottom expressions, 
it cancels out, leaving the number of patients with the event (1) 
divided by the number of patients without the event (4). 
The odds ratio is the odds of an event occurring in one group 
divided by the odds of the same event in another group. In the 
sheepskin trial, the odds ratio can be calculated by dividing the 
odds of getting an ulcer in the sheepskin group by the odds in 
the control group. 
The odds were about 0.11 in the sheepskin group and 0.20 in the 
control group. This means that the odds of developing an ulcer 
in the sheepskin group were 0.54 of that in the control group. 
Put another way, patients with a sheepskin overlay were half as 
likely to develop ulcers as patients given usual treatment.
Odds ratio is similar to relative risk. In the sheepskin trial the 
relative risk was 0.58 and the odds ratio was 0.54. For most 
clinical trials where the event rate is low, that is less than 10% 
= 0.5821
218
37
223
÷
= 0.5421
197
37
186
÷
Table 2
Relation between relative risk, absolute risk and odds ratio 2
In an overview of randomised controlled trials of hypertension management, rates of stroke were measured in patients 
randomised to receive the experimental treatment or control. Results were analysed according to the severity of hypertension.
Disease severity Event rate in 
control group 
(or AR)
Event rate in 
experimental group 
(or AR)
RR 
(RRR)
ARR NNT OR
Moderate hypertension 20% 12%
0.60
(0.40)
8% 13 0.54
Mild hypertension 1.5% 0.9%
0.60
(0.40)
0.6% 167 0.60
AR absolute risk
RR relative risk
RRR relative risk reduction
ARR absolute risk reduction
NNT  number needed to treat to prevent one stroke
OR odds ratio
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of all participants have an event, the odds ratio and relative risk 
can be considered interchangeable. The relative risk and odds 
ratio will also be closer together when the treatment effect is 
small (that is, odds ratio and relative risk are close to 1) than 
when treatment effect is large. However, as the event rate 
increases above 15% or as the treatment effect becomes huge, 
the odds ratio will progressively diverge from the relative risk. 
Fortunately, this is rarely a problem. Consider a meta-analysis 
of ligation versus sclerotherapy for oesophageal varices, which 
demonstrated a re-bleeding rate of 47% with sclerotherapy, as 
high an event rate as one is likely to find in most trials.3 The 
odds ratio associated with treatment with ligation was 0.52, a 
large effect. Despite the high event rate and large effect, the 
relative risk was 0.60, not very different from the odds ratio. 
Thus choosing one measure or the other is unlikely to have an 
important influence on most treatment decisions.
The odds ratio is gradually losing favour as a measure of 
treatment effect4, particularly as data from which relative risk 
is derived can also be used to calculate absolute risk reduction 
and number needed to treat, which are more clinically useful.
Hazard ratio
Hazard ratio is a measure of relative risk over time in 
circumstances where we are interested not only in the total 
number of events, but in their timing as well. The event of 
interest may be death or it may be a non-fatal event such as 
readmission or symptom change. 
Table 3 shows results of the study on pressure ulcers in 
hospitalised patients.1 Results were expressed in several ways 
including: 
n	 relative risk (row g), which is based on comparing the 
proportions of patients between groups who developed 
ulcers by study end (which the authors of the study termed 
cumulative incidence risk)
n	 incidence rate ratio (row i), which is a time-dependent relative 
risk comparing the rates of ulcers over time (in this case, per 
100 bed days) between groups.
Note that the relative risk and the incidence rate ratio were 
different, 0.58 versus 0.42, with the time-dependent relative risk 
suggesting a greater benefit from intervention than the overall 
relative risk, and which is also fairly close to the estimated 
hazard ratio of 0.39 (row j). 
In contrast to the overall relative risk, both the time-dependent 
relative risk and hazard ratio take into account the timing of 
events which may not be evenly distributed throughout the 
study period. 
The hazard ratio equals a weighted relative risk over the entire 
Table 3
Hazard ratio and time-to-event analysis 1
In a randomised controlled trial, 441 patients assessed on admission as having low to moderate risk of developing pressure 
ulcers were randomised to receive a sheepskin mattress overlay for the duration of hospital stay or usual treatment (control 
group) as determined by ward staff. Patients were followed for up to 20 days after randomisation and assessed daily for the 
onset of pressure ulcers. The results were reported as follows: 
Sheepskin group Control group
a. Total number of patients 218 223
b.  Total number of bed days observed 1728 1561
c.  Total number of ulcers 27 58
d.  Number of patients with ulcer(s) 21 37
e.  Mean bed days per patient 7.9 7.0
f.  Cumulative incidence risk (95% CI) 9.6% (6.1%–14.3%) 16.6% (12.0%–22.1%)
g.  Relative risk 0.58 (0.35–0.96) 1.0 (referent group)
h.  Incidence rate per 100 bed days (95% CI) 1.6 (1.0–2.3) 3.7 (2.8–4.8)
i.  Incidence rate ratio (95% CI) 0.42 (0.26–0.67) 1 (referent group)
j.  Hazard ratio 0.39 (0.22–0.69) 1 (referent group)
CI confidence interval
Cumulative incidence risk (f) is the total number of patients who developed one or more ulcers (d)/number of patients for each 
group (a).
Relative risk (or risk ratio) (g) is the ratio of cumulative incidence risk (f) in sheepskin vs control group (9.6%/16.6% = 0.58).
Incidence rate (h) per 100 bed days is the total number of ulcers (c)/total number of bed days observed (b).
Incidence rate ratio (i) is the ratio of incidence rate per 100 bed days (h) in sheepskin vs control group (1.6/3.7 = 0.42).
Hazard ratio (j) is estimated using Cox proportional hazards regression applied to Kaplan-Meier time-to-event curves for ulcer-free 
survival (Fig. 1).
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duration of a study and is derived from a time-to-event curve 
or Kaplan-Meier curve. This curve describes the status of both 
patient groups at different time points after a defined starting 
point. In the sheepskin study, events in the intervention group 
are not only less frequent overall than in the control group 
but they are delayed in time (Fig. 1). As some patients will be 
followed for a longer period of time than others (because they 
were recruited or randomised into the trial at an earlier time 
or because they remained in the study while others dropped 
out), the time-to-event curve usually extends beyond the mean 
follow-up duration. 
As the trial progresses, at some point prediction of treatment 
effect becomes very imprecise (in our example at 20 days) 
because there are few patients available to estimate the 
probability of the outcome of interest. Confidence intervals 
around the survival curves would capture the precision of 
the estimate. Ideally then, we would estimate relative risk by 
applying an average, weighted for the number of patients 
available, over the entire study duration. Statistical methods 
allow just such an estimate which is the hazard ratio.
This derived (or 'crude') hazard ratio then needs to be 'adjusted' 
or corrected for differences in the two groups at baseline that 
might influence the outcome of interest. This issue is less of a 
concern if randomisation has rendered both groups similar in 
terms of their baseline characteristics. In our example, patients 
in the intervention group compared to control were older 
(mean age 63.2 years vs 61.1 years), more acutely ill (51% were 
emergency admissions vs 43%), and had greater prevalence 
of medical, as opposed to surgical, diagnoses (35% vs 27%). 
Applying the Cox proportional hazards regression model 
produces an adjusted hazard ratio which takes account of such 
imbalances. 
In every other way the hazard ratio is similar to odds ratio and 
relative risk wherein treatment efficacy is denoted by a hazard 
ratio of less than 1.0 in prevention trials and a hazard ratio of 
more than 1.0 in treatment trials. 
Statistical significance
If there is a statistically significant difference in outcomes 
between treatment and control groups, the observed difference 
is very unlikely to have occurred due to the play of chance, even 
after accounting for imprecision in the difference related to the 
total number of events in both groups.
P values
Statistical significance is defined arbitrarily in terms of a p value 
of less than 0.05. The p value however does not directly indicate 
the chance of an effect being present or not being present. 
Instead it tells us how often chance alone would give apparently 
favourable results. A p value of less than 0.05 tells us that there 
is less than 5% probability that chance alone would lead to such 
favourable results, but it says nothing directly about whether 
chance is the best explanation for the results. 
Confidence intervals
Confidence intervals give us an estimate of the precision of the 
results. Conventionally 95% confidence intervals are used which, 
if the same trial were to be repeated many times over, define the 
range of values within which the true estimate would be found in 
95% of occasions. The confidence interval represents the range of 
values within which we are 95% confident that the true population 
estimate lies. If the number of events such as death occurring over 
time is fairly small (as occurs with small samples and/or low case 
fatality rate), then the precision with which the true probability of 
the event can be estimated is relatively low, as reflected in wider 
confidence intervals. Narrower confidence intervals indicate more 
precise results. The 95% confidence intervals represent almost two 
standard deviations around the mean.
Fig. 1
Kaplan-meier curve for time to onset of first  
pressure ulcer *
*  Jolley DJ et al. Preventing pressure ulcers with the Australian 
medical sheepskin: an open-label randomised controlled trial. 
MJA 2004;180:324–327. ©Copyright 2004. The Medical Journal of 
Australia – reproduced with permission.
Kaplan-Meier estimates show the time to onset of first 
pressure ulcer in 441 hospitalised patients at risk of 
developing pressure ulcers. Patients were randomised 
to receive either a sheepskin mattress overlay or usual 
treatment (referent group). 
Predicting the effect of the sheepskin intervention becomes 
very imprecise as the number of patients in each group 
decreases with time.
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It is important to remember that the result is statistically 
significant if the confidence intervals do not cross the null value, 
such as 1.0 for relative risk and 0 for absolute risk reduction. 
Conclusion
An understanding of the commonly used statistical measures 
of benefit is necessary if clinicians are to gain an appreciation 
of the efficacy of different therapies. For the majority of 
clinical trials, relative risk and odds ratio can be considered 
interchangeable as a measure of the relative change in the risk 
of a preventable event. The hazard ratio is a related measure 
that weights the risk change according to when events occur 
over time. Absolute risk reduction represents the absolute 
change in risk (expressed in percentage points) and its 
reciprocal represents the number of patients who would need to 
be treated over a given period of time to prevent one event.
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on the correct use of eye drops
Michael Steiner, Eye Surgeon, Sydney
Summary
Drops are a common vehicle for administering 
drugs to the eye, but they must be instilled 
correctly. To limit wastage and systemic 
absorption a single drop should usually be 
prescribed. If the patient needs to use two types 
of drop their instillation should be separated by 
at least three minutes. most eye drops contain a 
preservative, but they should not be kept beyond 
the expiry date on the label.
Key words: expiry dates, instillation, ophthalmic solutions.
(Aust Prescr 2008;31:16–17)
Introduction
Patients should be instructed on how to use their eye drops. 
They need to know about the frequency and the method of 
administration, and how the drops should be stored.
one drop or two? 
Only one drop should be used at a time. A second drop may 
wash out the first or increase the possibility of systemic 
absorption and toxicity. A second drop can often end up on the 
skin of the eyelids and the patient is then more likely to develop 
a contact allergy. Using two drops also doubles the cost of the 
medication.
How often?
The type of drug and the patient's condition determine 
the frequency of instillation. In some serious infective or 
inflammatory conditions the drops may need to be used 
as frequently as half hourly (although generally only while 
the patient is awake). In contrast, the most commonly used 
treatments for glaucoma only need to be instilled once a day.
How to use eye drops
The method of instilling the drops is important. If it is not done 
properly, the drops have almost as much chance of landing on 
the cheek as in the eye.
It is important that patients wash their hands and remove any 
contact lenses before using the drops. Many eye drops contain 
the drug in suspension rather than in solution. These drops 
should always be shaken before use.
The cap should be removed from the bottle but never put down 
on the table in such a way that it may become contaminated. 
It should either be put on its side or held carefully in the other 
hand.
During instillation it is very important that patients do not touch 
their eye with the tip of the bottle. This could both abrade the 
cornea and contaminate the remaining drops.
In the traditional method of instilling drops (see Fig. 1) the bottle 
is held upside down in one hand between the thumb and index 
finger and with the other hand the lower eyelid is gently pulled 
